

CGI Pharmaceuticals Inc.

[View the current CGI Pharmaceuticals Inc. Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/20725-CGI+Pharmaceuticals+Inc..html)

(<http://www.bioportfolio.com/biorporate/20725-CGI+Pharmaceuticals+Inc..html>)

Contact Details:

36 East Industrial Road

Branford

Connecticut

06405

United States of America

Tel: (203) 315-1222

Fax: (203) 488-7838

Email: jobs@cgipharma.com

CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule kinase inhibitors for a broad range of oncology/angiogenesis and autoimmune/allergic/inflammatory disease indications. The Company's fully integrated drug discovery infrastructure comprises proprietary discovery biology and chemistry, extensive lead generation capabilities, as well as preclinical and growing clinical development expertise.

Recent Publications by CGI Pharmaceuticals Inc.:



- [Chemical genetic approaches to kinase drug discovery.](#)

Chemical genetics is an important approach in biological research that... 18th October, 2005

CGI Pharmaceuticals Inc, 36 East Industrial Road, Branford, CT 06405, USA.- *Curr Opin Drug Discov Devel.* 2005 Sep;8(5):638-45.

Press Releases on CGI Pharmaceuticals Inc.:

| | | | |
|--|---------------------|----------------------------|--|
| "As an Industry, We've Been too Focused on Regulatory Approval." Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit. | 26th November, 2009 | | LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes |
| Onyx Pharmaceuticals Announces December 2009 Investor Events | 25th November, 2009 | Onyx Pharmaceuticals, Inc. | EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25 |
| Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference | 25th November, 2009 | Ardea Biosciences, Inc. | /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper |
| iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering | 25th November, 2009 | | DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals's service division and Pyxis Discovery announced today that they have signed a collaborative agreement |
| Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective | 25th November, 2009 | Reportlinker | NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www |

CGI Pharmaceuticals Inc. Patents:



- 7405295- [Certain imidazo\[1,2-a\]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds](#)
- 7393848- [Certain heterocyclic substituted imidazo\[1,2-A\]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds](#)
- 7312341- [6-aryl-imidazo\[1,2-a\] pyrazin-8-ylamines, method of making, and method of use thereof](#)
- 7259164- [Certain substituted imidazo\[1,2-a\]pyrazines, as modulators of kinase activity](#)
- 7189723- [Certain 8-heteroaryl-6-phenyl-imidazo\[1,2-a\]pyrazines as modulators of kinase activity](#)
- 7160885- [Certain 6, 8-\(heteroaryl or aryl\) disubstituted imidazo\[1,2-a\]pyrazines as modulators of Hsp90 complex activity](#)
- 7015227- [Certain amino-substituted monocycles as kinase modulators](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:Peter.Barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

